CLINICAL ROLE -
Managing Complexity in Oncology
Recently published data from a survey of commercial health plans reveal the latest trends and emerging strategies in oncology management.
Antifungal Drug Shows Promise in Treatment of Prostate Cancer
Understanding the Impact of the Specialty Pharmacist on Quality and Effective Medication Management: Providing Individualized Care in Rheumatoid Arthritis
This activity provides information for pharmacists regarding current and emerging therapies to slow disease progression in patients with rheumatoid arthritis.
Less Expensive Prostate Cancer Treatment May Prove Effective
Long-Term Use of Statins May Reduce Lung Cancer Mortality
Smoking Doubles Risk of Prostate Cancer Recurrence After Surgery
Some Lung Cancer Patients May Benefit from Melanoma Drug
Benefit of Lung Cancer Drug Determined by Disease Severity
Protecting Health Care Workers from Chemotherapeutic Medication
Proposed regulations call for the use of closed-system transfer devices by health care professionals who handle hazardous drugs.
Afinitor by Novartis Pharmaceuticals, Inc
Afinitor (everolimus) is approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
Specialty Pipeline Highlights
Anticipated near-term specialty drug approvals include new therapies for cancer, orphan conditions, high cholesterol, and asthma.
Improving Medication Adherence for Oncology Patients Through High-Tech Interventions
Mobile adherence apps are a great boon to patients who face the responsibility of taking oral chemotherapy drugs as directed without in-person supervision by clinicians.
Big Data and the Specialty Oncology Pharmacist: Needs and Challenges
Pharmaceutical companies and clinical oncology teams are collaborating to harness large sets of patient data, paving the way for more informed and individualized decision-making about treatments.
Oncology: An Ever-Growing Presence in Specialty Pharmacy
As oncology spending rises, insurers and manufacturers are looking to specialty pharmacy programs to maximize the effectiveness of cancer therapies.
Oncology Limited Distribution Networks Balance Risk with Opportunity
There are several key factors a specialty pharmacy must consider when deciding whether to participate in a limited distribution network.
Overview of Year-to-Date 2015 Oncology Approvals
New drug approvals include therapies for patients with breast cancer, thyroid cancer, neuroblastoma, and multiple myeloma.
Oncology Drugs and the Coming Policies That May Redefine Their Use
Cost containment of medications for the treatment of cancer is an area of increasing concern for specialty pharmacy stakeholders.
The Future Is Now in Oncology
